B37.1 Pulmonary candidiasis

Name of the Condition

• Pulmonary Candidiasis (ICD Code: B37.1)
• Technical term: Pulmonary candidiasis
• ICD-10 Code: B37.1

Summary

Pulmonary candidiasis is a fungal infection of the lungs caused by Candida species, typically Candida albicans. It occurs when Candida overgrows in the respiratory tract, leading to inflammation and potential tissue damage. The condition may present as a primary infection or secondary to systemic candidiasis, affecting lung tissue and airways.

Causes

Pulmonary candidiasis results from the overgrowth of Candida fungi, which are part of the normal flora in the respiratory tract. This overgrowth can be triggered by factors such as impaired immune function, prolonged antibiotic use, or invasive medical procedures. Inhalation of fungal spores or hematogenous spread from other sites may also contribute.

Risk Factors

• Weakened immune system (e.g., HIV/AIDS, chemotherapy, organ transplantation).
• Prolonged use of broad-spectrum antibiotics or corticosteroids.
• Chronic lung diseases (e.g., COPD, cystic fibrosis).
• Mechanical ventilation or indwelling pulmonary devices.
• Diabetes mellitus or poorly controlled blood sugar.
• Recent surgery or trauma to the chest.

Symptoms

• Persistent cough, often with sputum production.
• Fever, chills, or night sweats.
• Shortness of breath or difficulty breathing.
• Chest pain or discomfort.
• Fatigue or malaise.
• In severe cases, respiratory distress or hypoxemia.

Diagnosis

Diagnosis involves a combination of clinical evaluation, imaging studies (e.g., chest X-ray or CT scan), and laboratory testing. Sputum cultures, bronchoalveolar lavage, or tissue biopsy may identify Candida species. Blood tests for fungal antigens or PCR may support the diagnosis, especially in systemic cases.

Treatment Options

• Antifungal medications: Oral or intravenous formulations (e.g., fluconazole, amphotericin B) based on severity and species.
• Duration of therapy varies, typically 2–6 weeks or longer for severe infections.
• Supportive care, including oxygen therapy or mechanical ventilation if needed.
• Addressing underlying risk factors (e.g., immunosuppression, device removal).

Prognosis and Follow-Up

Prognosis depends on the patient’s immune status, infection severity, and timely treatment. Immunocompetent patients often recover fully with appropriate therapy, while immunocompromised individuals may face higher risks of recurrence or complications. Follow-up includes monitoring for symptom resolution and repeat imaging or cultures if needed.

Complications

• Respiratory failure or acute respiratory distress syndrome (ARDS).
• Disseminated candidiasis (spread to other organs).
• Lung abscesses or cavitation.
• Chronic lung damage or fibrosis in severe cases.

Lifestyle & Prevention

• Maintain good respiratory hygiene and avoid exposure to fungal spores in high-risk environments.
• Manage underlying conditions (e.g., diabetes, immune disorders) to reduce susceptibility.
• Promptly address respiratory infections or device-related risks (e.g., ventilator-associated pneumonia).
• Follow healthcare provider guidance for prophylactic antifungals in high-risk settings.

When to Seek Professional Help

Seek immediate medical attention if experiencing severe respiratory symptoms (e.g., difficulty breathing, chest pain) or signs of systemic infection (e.g., high fever, confusion). Persistent cough, unexplained weight loss, or recurrent infections also warrant evaluation.

Tips for Medical Coders

• Code B37.1 is specific to pulmonary candidiasis; ensure documentation confirms lung involvement (e.g., imaging, respiratory symptoms).
• Differentiate from other fungal lung infections (e.g., aspergillosis) or bacterial pneumonia, which require distinct codes.
• Include details on infection severity, immune status, or treatment response if available to support clinical coding accuracy.